Academia

Two Americans and a British scientist share the 2020 Prize for Physiology or Medicine for work in the 1970s through the 1990s. The rise of agents to treat hepatitis C virus has created vexing questions in managed care.

During a 1-hour free webinar from MJH Life Sciences™’s COVID-19 Coalition, experts discussed various myths around the coronavirus disease 2019 (COVID-19) pandemic.

Differences in long-term outcomes in patients with rheumatoid arthritis (RA) may because RA with and without autoantibodies are actually 2 distinct conditions.

A new review article said there are hurdles to bringing minimal residual disease (MRD) into the clinic as a decision-making tool, but the day is likely not far away.

The study is part of Moderna’s larger trial to find a vaccine to prevent coronavirus disease 2019, which puts older adults, who have weaker immune responses, at a higher risk of more severe illness and death.

Higher body mass index based on genes is associated with a risk of developing rheumatoid arthritis, according to an analysis of genetic data published in Arthritis & Rheumatology.

Amid the COVID-19 pandemic, health professionals reported difficulty accessing Parkinson disease medications, particularly in low-income countries, leading to greater disability of patients as a result.

Patients of South Asian origins who have psoriatic arthritis have a worse clinical phenotype and worse disease impact than patients of North European origins, according to research published in Rheumatology.

In individuals with type 2 diabetes with no previous insulin treatment, once-weekly injections of insulin icodec resulted in glucose-lowering efficacy and a safety profile similar to individuals who took once-daily insulin glargine U100.

To the extent that some factors are modifiable, the takeaway for clinicians is to encourage their patients with multiple sclerosis (MS) to adopt healthy habits.

The drug, mastinib, reduced the chance of a confirmed disability progression by 37% in phase 2b/3 study results.

With more multiple sclerosis (MS) treatments becoming available, it is now possible to better personalize approaches, explained speakers during a session at MSVirtual 2020: 8th Joint ACTRIMS-ECTRIMS Meeting.

The broadest real-life study of dupilumab in atopic dermatitis (AD) found significant improvements in adults with moderate to severe AD that were even greater than the results reported in clinical trials.

In recent years, the number of children diagnosed with additional autoimmune diseases accompanying type 1 diabetes (T1D) has increased, according to a study published in Frontiers in Endocrinology.

Secukinumab 150 mg improves signs and symptoms of patients with nonradiographic axial spondyloarthritis, according to results of the PREVENT trial published in Arthritis & Rheumatology.

Although the effects of stress and anger on ischemic heart disease and arrhythmia are well known, they are less established in heart failure, particularly those with reduced ejection fraction.

A new study of patients with rheumatoid arthritis (RA) in Korea has shown that only about half of patients with RA who attained clinical remission were also in imaging remission.

Patients with connective tissue diseases are at greater risk for severe coronavirus disease 2019 (COVID-19) than patients with chronic inflammatory arthritis.

Screening women aged 40 to 49 years for breast cancer reduced mortality by 25% in the first 10 years compared with waiting until at age 50 years and older, which is the common practice in the United Kingdom.

As the American Society of Clinical Oncology calls for more aggressive efforts to bring equity to cancer care, authors in JAMA Oncology say COVID-19 is creating wider gaps.

Given the constraints prevalent post-COVID-19, Dr Mark Fendrick, director of the University of Michigan Center for Value-Based Insurance Design, stresses that it is now more important than ever for the health care industry to prioritize payment reform, value-based benefit design, and novel policy initiatives.

A Marshall University researcher received $444,000 from NIH to continue researching a new treatment target in chronic renal failure.

Real-world outcomes are important because the populations included in clinical trials rarely reflect the populations actually being treated in the clinic, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.

When seniors with cancer are being treated with combination therapies, providers need to keep in mind more than just the complex regimens they’re administering, said Ginah Nightingale, PharmD, associate professor of pharmacy practice at Jefferson College of Pharmacy.

Research has shown disparities in multiple myeloma treatment between clinical trials and real-world outcomes, as well as a lot of heterogeneity among treatment patterns by age and region, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.

For 34 years, Ochsner Health System has annually recognized scientists who have made major contributions regarding the relationship between smoking and disease along with the development of innovative treatment modalities.

Outside of breast cancer, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have not been as successful as tumors develop resistance. New research shows that a murine double minute (MDM2) antagonist can help CDK4/6 inhibitors overcome resistance, offering a potential second-line treatment option in melanoma.

Value-based programs such as accountable care organizations appear to encourage the adoption and spread of care coordination activities by hospitals.

The survey aimed to better understand the perceptions, experiences, and educational needs of patients who have nonmotor symptoms of Parkinson disease as well as their caregivers.

From 2013 to 2017, the population of US patients prescribed treatment for chronic hepatitis C virus (HCV) changed, becoming predominantly treatment-naïve and having received care in nonacademic centers.